Compare NSPR & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | ELUT |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 42.5M |
| IPO Year | 2009 | 2020 |
| Metric | NSPR | ELUT |
|---|---|---|
| Price | $0.76 | $0.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 48.1K | 44.0K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | ★ N/A | N/A |
| Revenue | $2,310,000.00 | ★ $12,293,000.00 |
| Revenue This Year | $57.98 | N/A |
| Revenue Next Year | $95.41 | $10.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $0.50 |
| 52 Week High | $2.57 | $1.39 |
| Indicator | NSPR | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 45.16 |
| Support Level | $0.66 | $0.51 |
| Resistance Level | $1.03 | $1.03 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 9.78 | 21.35 |
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.